Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript
Emergent BioSolutions Inc., (EBS)
Q2 2009 Earnings Call
August 6, 2009 5:00 pm ET
Executives
Robert G. Burrows – Vice President, Investor Relations
Fuad El-Hibri – Chairman of the Board, Chief Executive Officer
R. Don Elsey – Chief Financial Officer
Daniel J. Abdun-Nabi – President, Chief Operating Officer
W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer
Analysts
Eric Schmidt [...]
August 14, 2009
Tags: Business, Chairman, Chief executive officer, Chief financial officer, Chief operating officer, Emergent BioSolutions, finance, fuad el-hibri, Investor relations, Shareholders, US government, Vice president Posted in: Board of Directors, CEO, Emergent BioSolutions, Management, Shareholders, fuad, fuad el-hibri 
No Comments
Emergent Biosolutions Appoints Dr. W. James Jackson As Chief Scientific Officer
Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James Jackson, Ph.D., has been appointed chief scientific officer, effective immediately. Dr. Jackson will report directly to Fuad El-Hibri, chairman and chief executive officer.
As CSO, Dr. Jackson will lead the company’s scientific evaluation of new products and technology platforms and will be responsible for building and [...]
July 13, 2009
Tags: Anthrax vaccines, Biotechnology and Pharmaceuticals, Business, Chief executive officer, Infectious disease, Pharmaceutical, Research and development, U.S. Food and Drug Administration, University of Georgia. Posted in: Uncategorized No Comments
Emergent Biosolutions And Ninebio Sdn. Bhd. Announce Joint Venture In Malaysia
Newly formed company to focus on creating critical R&D and manufacturing infrastructure and supplying biodefense countermeasures within Asia and other territories.
January 24, 2008 – Emergent BioSolutions (NYSE: EBS) and Ninebio Sdn. Bhd. (“9Bio”) today announced the formation of a joint venture in Malaysia that will focus on creating critical biologics infrastructure and supplying biodefense countermeasures, [...]
July 13, 2009
Tags: Business, Chief executive officer, Emergent BioSolutions, MALAYSIA, National Institutes of Health, Private Securities Litigation Reform Act, Research and development, SEC, U.S. Food and Drug Administration, United States. Posted in: Uncategorized No Comments